Welcome to our dedicated page for Theravance Biopharma news (Ticker: TBPH), a resource for investors and traders seeking the latest updates and insights on Theravance Biopharma stock.
Theravance Biopharma, Inc. (NASDAQ: TBPH) is a leading biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. The company's mission is to pioneer a new generation of small-molecule drugs that better meet patient needs by maximizing efficacy while limiting systemic side effects.
Theravance Biopharma has a strong focus on inflammation and immunology and aims to deliver Medicines that Make a Difference® in people's lives. The company's research expertise has led to the development of the FDA-approved YUPELRI® (revefenacin) inhalation solution, the first once-daily, nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Theravance Biopharma co-promotes YUPELRI with Viatris Inc. under a profit and loss sharing arrangement.
Another promising product in Theravance Biopharma's pipeline is ampreloxetine, a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA). This drug has the potential to be a first-in-class therapy, addressing a significant unmet medical need for MSA patients.
The company is also involved in strategic collaborations with other pharmaceutical companies to expand its reach and enhance its product pipeline. Their current projects and partnerships are aimed at furthering the development and commercialization of innovative therapies.
Financially, Theravance Biopharma has shown consistent performance, with significant growth in YUPELRI net sales and robust clinical trial activity. Recent achievements include positive results from a Phase III clinical trial of YUPELRI in China and ongoing enrollment in the Phase 3 CYPRESS study for ampreloxetine. These milestones underscore the company's commitment to delivering impactful therapies and driving shareholder value.
Theravance Biopharma continues to leverage its organ-selective drug development expertise to create value and improve patient outcomes. For more information, please visit www.theravance.com.
Theravance Biopharma (NASDAQ: TBPH) will present at the SVB Leerink 11th Annual Global Healthcare Conference on February 16, 2022, at 3:40 pm ET. A webcast of the event is available on Theravance.com and will be archived for 30 days.
Theravance Biopharma focuses on developing respiratory medicines, with its flagship product being YUPELRI®, an FDA-approved inhalation solution for chronic obstructive pulmonary disease (COPD). The company is also associated with potential payments from Glaxo Group Limited through agreements with Innoviva, Inc..
Theravance Biopharma (NASDAQ: TBPH) has enrolled the first patient in a Phase 4 study for YUPELRI® (revefenacin), a once-daily nebulized bronchodilator for COPD treatment. The PIFR-2 study aims to compare lung function improvements in patients using YUPELRI versus SPIRIVA® over 12 weeks, involving 366 participants. Results are expected in Q1 2023. This initiative seeks to expand YUPELRI’s market reach, enhancing its competitive position alongside the strategic collaboration with Viatris for commercialization.
Theravance Biopharma (NASDAQ: TBPH) will present at the J.P. Morgan 40th Annual Healthcare Conference on January 13, 2022, at 12:00 PM ET. The webcast can be accessed on the company's website under the Investors section, and a replay will be available for 30 days. Theravance focuses on respiratory medicines, boasting FDA-approved YUPELRI® for COPD. The company is committed to developing transformative therapies to improve respiratory health.
Theravance Biopharma (NASDAQ: TBPH) will participate in the Evercore ISI 4th Annual HEALTHCONx Virtual Conference on November 30, 2021, at 11:20 am ET. The webcast can be accessed under the Investors section on Theravance.com and will be available for 30 days afterward. The biopharmaceutical company focuses on developing respiratory medicines, including the FDA-approved YUPELRI (revefenacin) for treating COPD. The company aims to enhance patient lives through innovative respiratory therapies.
Theravance Biopharma (TBPH) reported Q3 2021 financial results, showing total revenue of $13.2 million, down $5.1 million from Q3 2020. The decrease was primarily due to reduced collaboration revenue from Janssen. YUPELRI revenue was $10.4 million, reflecting a 7% year-over-year increase. The company aims for cash-flow positivity by H2 2022, planning a 75% workforce reduction by February 2022. R&D expenses decreased to $43.7 million from $67.4 million year-over-year, while operating loss improved to $53.6 million from $76.6 million.
Theravance Biopharma (NASDAQ: TBPH) will report its third quarter 2021 financial results on November 3, 2021, after market close. A conference call will follow at 5:00 PM ET. The call can be accessed by dialing (855) 296-9648 domestically or (920) 663-6266 internationally, using confirmation code 9772385. Company highlights include its focus on respiratory medicines and notable products like YUPELRI for COPD. Future financial benefits may arise from agreements with GSK related to certain programs.
Theravance Biopharma (NASDAQ: TBPH) announced significant strategic actions aimed at enhancing shareholder value, including a 75% workforce reduction, affecting around 270 positions, with expected completion by February 2022. The company anticipates annualized operating expense savings of approximately $165 million in 2022. Updated financial guidance projects R&D expenses to drop from $195-225 million in 2021 to $55-65 million in 2022, while SG&A expenses are expected to reduce to $30-40 million. The firm plans to focus on its respiratory therapeutic portfolio, notably YUPELRI and TRELEGY, aiming for positive cash flow in the second half of 2022.
Theravance Biopharma (NASDAQ: TBPH) announced that its Phase 3 study of ampreloxetine for treating symptomatic neurogenic orthostatic hypotension (nOH) did not meet the primary endpoint. While mild to moderate adverse events were reported, no serious side effects were attributed to the drug. The company plans to analyze the findings further and present results at a future scientific forum. CEO Rick E Winningham expressed disappointment, highlighting the unmet need for effective treatments for nOH.
Theravance Biopharma (NASDAQ: TBPH) announced disappointing top-line results from its Phase 2b induction study of izencitinib for ulcerative colitis. The study failed to meet its primary endpoint of change in total Mayo score and the secondary endpoint of clinical remission at week 8 compared to placebo. However, izencitinib was well-tolerated, showing similar adverse event rates to placebo. The company plans to further analyze the study data and upcoming results from ongoing studies, including a Crohn's Phase 2 study expected in early 2022.
Theravance Biopharma reported its Q2 2021 financial results, highlighting a total revenue of $12.9 million, a decrease of $2.1 million year-over-year. Revenue from YUPELRI collaboration with Viatris was $10.9 million, translating to a 35% share of net sales. R&D expenses reduced to $51.1 million, while SG&A expenses rose to $25.9 million. The company closed a public offering raising $115.6 million and anticipates key clinical results for its products in upcoming quarters. Cash position remains strong at $265 million.
FAQ
What is the current stock price of Theravance Biopharma (TBPH)?
What is the market cap of Theravance Biopharma (TBPH)?
What is Theravance Biopharma's primary focus?
What is YUPELRI?
What is ampreloxetine?
Who are Theravance Biopharma’s strategic partners?
What recent achievements has Theravance Biopharma made?
Where can I find more information about Theravance Biopharma’s products?
What is the purpose of the CYPRESS study?
How does Theravance Biopharma create shareholder value?
What is Theravance Biopharma’s mission?
How can I listen to Theravance Biopharma's conference calls?
